Developing new methods to create important sulfur-based drugs using data science
Generality-Oriented Development of Novel Methods for the Synthesis of Enantioenriched Sulfondiimines Using Data Science
['FUNDING_FELLOWSHIP'] · UNIVERSITY OF UTAH · NIH-11071256
This study is working on making a special type of compound that could help create better and safer cancer treatments, using smart technology to improve how these compounds are made, which could lead to more effective options for patients like you.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF UTAH (nih funded) |
| Locations | 1 site (SALT LAKE CITY, UNITED STATES) |
| Trial ID | NIH-11071256 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the synthesis of sulfondiimines, which are sulfur-containing compounds crucial for developing effective anti-cancer drugs. By utilizing data science and computational chemistry, the project aims to optimize the synthesis process, making it more efficient and selective for specific drug forms. Patients may benefit from the development of safer and more effective cancer treatments as a result of these advancements. The research will explore general conditions that can be applied to various compounds, enhancing the overall drug development process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancer who may benefit from new anti-cancer therapies.
Not a fit: Patients who do not have cancer or are not seeking new treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the creation of safer and more effective anti-cancer medications.
How similar studies have performed: Other research has shown promise in using data science for drug synthesis, indicating potential success for this approach.
Where this research is happening
SALT LAKE CITY, UNITED STATES
- UNIVERSITY OF UTAH — SALT LAKE CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SLOCUMB, HANNAH — UNIVERSITY OF UTAH
- Study coordinator: SLOCUMB, HANNAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, Cancer Drug